Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 21;7(5):e877.
doi: 10.1097/HS9.0000000000000877. eCollection 2023 May.

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

Verena I Gaidzik  1 , Peter Paschka  1   2 , Richard F Schlenk  3 , Daniela Weber  1 , Stefan Fröhling  4 , Alwin Krämer  3   5 , Ralph Wäsch  6 , Jörg Westermann  7 , Karin Mayer  8 , Maike de Wit  9 , Walter Fiedler  10 , Axel Benner  11 , Michael Heuser  12 , Felicitas Thol  12 , Konstanze Döhner  1 , Arnold Ganser  12 , Hartmut Döhner  1
Affiliations

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

Verena I Gaidzik et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

VIG: Consulting or advisory board membership: Jazz Pharmaceuticals; Speakers bureau: Abbvie, Janssen, Pfizer; Travel or accommodation expenses: AbbVie. PP: Consulting or advisory board membership: AbbVie, Agios, Astellas, Astex, Bristol-Meyers Squibb, Celgene, Jazz, Novartis, Otsuka, Pfizer, Sunesis; Speakers bureau: AbbVie, Agios, Astellas, Bristol-Meyers Squibb, Celgene, Jazz, Novartis, Pfizer; Travel or accommodation expenses: AbbVie, Amgen, Bristol-Meyers Squibb, Celgene, Janssen, Novartis, Takeda. RFS: Consulting or advisory board membership: Abbvie, Agios, Astellas, Celgene, Daiichi Sankyo, Hexal, Neovio Biotech, Novartis, Pfizer, Roche; research funding: Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Roche; speakers bureau, Astellas, Pfizer. SF: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche. AK: Consulting, honoraria, advisory board membership: Roche; research funding: BMS, Roche. RW: Consulting or advisory board: Janssen, Novartis, BMS/Celgene, Amgen, Gilead, Pfizer, Sanofi, Takeda; research funding: Janssen, Sanofi; Honoraria: Abbvie, Sanofi, Takeda, Janssen, Amgen, BMS/Celgene, Gilead, Pfizer. JW: Consulting or advisory board membership: Novartis, Bristol Myers Squibb, Celgene, Amgen, Abbvie, Agios, Jazz, Pfizer, Sanofi, Sobi, Astellas. MdW: Research funding: Pfizer, Abbvie, Novartis, Astellas, Bristol Myers Squibb, AstraZeneca, MorphoSys; speakers honoraria: AstraZeneca, Janssen; travel or accommodation expenses: Astellas, Janssen. WF: Consulting or advisory board membership: AbbVie, Amgen, Celgene, Jazz Pharmaceuticals, MorphoSys AG, Novartis, Pfizer; Stemline and Clinigen; research funding: from Amgen and Pfizer; patents and royalties: Amgen; travel or accommodation expenses: Amgen, Daiichi Sankyo, Gilead, Jazz Pharmaceuticals, and Servier. MH: Consulting or advisory board: Abbvie, BMS/Celgene, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, Roche, Tolremo. Honoraria: Jazz Pharmaceuticals, Janssen, Novartis; research funding: Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Jazz Pharmaceuticals, Karyopharm, Novartis, Pfizer, Roche. FT: Consulting or advisory board: Abbvie, Astellas, Bristol Myers Squibb/Celgene, Jazz Pharmaceuticals, Novartis, Pfizer. KD: Consulting or advisory board: Novartis, Celgene/BMS, Abbvie, Jazz Pharmaceuticals; research funding: Novartis; Celgene/BMS, Astellas, Agios, Kronos; Honoraria: Novartis, Celgene/BMS, Jazz Pharmaceuticals. HD: Consulting or advisory board: AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz, Novartis, Servier, Syndax; Clinical Research Funding to Institution: AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, Pfizer. All the other authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Kaplan-Meier plot for overall survival of all enrolled patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bill M, Mrózek K, Kohlschmidt J, et al. . Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci U S A. 2020;117:26340–26346. - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian RP, et al. . International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200–1228. - PMC - PubMed
    1. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B cell pre-cursor acute lymphoblastic leukaemia. Blood Rev. 2012;26:123–135. - PubMed
    1. Döhner H, Estey E, Grimwade D, et al. . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447. - PMC - PubMed
    1. Döhner H, Wei AH, Appelbaum FR, et al. . Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022:blood.2022016867. Epub ahead of print. - PubMed